SCOTUS delays abortion pill ruling; Mindpath offers cautionary tale for private equity in mental health

The Supreme Court has delayed its ruling on whether the abortion pill mifepristone can remain on the market until at least Friday.

April 19, 2023 Check out STAT+

Sponsored By

STEFANI REYNOLDS/AFP via Getty Images Supreme Court delays ruling on abortion pill restrictions The Supreme Court has delayed its ruling on whether the abortion pill mifepristone can remain on the market. By Sarah Owermohle STAT+ | Mindpath seemed like a success story for private equity in mental health. Now, it's a cautionary tale As private equity increasingly wades into mental health clinics, Mindpath's stumbles are a neon red warning sign for the field. By Olivia Goldhill CDC advisory panel backs changes to Covid vaccination policy The ACIP was not asked to vote on the changes but appeared broadly supportive of the new guidance from the FDA. By Helen Branswell Courtesy Vivian Cheung; Photo Illustration: Christine Kao/STAT Discrimination lawsuit against HHMI spotlights barriers faced by scientists with disabilities HHMI, one of the largest private funders of biomedical research, has vigorously denied its decision had anything to do with her disability. By Julia Métraux STAT+ | STAT-Harris Poll: Most Americans are worried about RSV The survey found that 71% of Americans who are familiar with the virus are concerned their children may contract RSV. By Ed Silverman STAT+ | Relay's breast cancer drug proves tolerable, but market is unimpressed The drug attacked mutations precisely, without causing a common toxic side effect. But it did little to shrink tumors. By Angus Chen Adobe STAT+ | Amazon strikes partnership with 3M to advance conversational AI in medicine Amazon has struck a partnership with 3M, which will use the tech giant's Bedrock suite for its Fluency Align medical scribe tool. By Brittany Trang STAT+ | PhRMA execs paint grim picture of industry under Medicare drug price negotiation In a briefing with reporters, PhRMA executives painted a grim picture of the industry under Medicare drug price negotiation. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser